QNCX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Quince Therapeutics Inc (QNCX) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock has been downgraded by multiple analysts due to the failure of its pivotal Phase 3 NEAT clinical trial, which was its core value driver. The company's financials are weak, with no revenue and significant losses. Additionally, there are no positive trading signals or catalysts to suggest a recovery in the near term.
The MACD is positive and expanding, but the RSI is neutral at 29.862, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level (S1: 0.0958), with no clear upward momentum. Overall, the technical indicators suggest a bearish trend.
NULL identified. There are no recent news updates, no positive trading signals, and no significant insider or hedge fund activity.
The company's core program has been discontinued, and its cash and debt levels are approximately equal, suggesting no intrinsic value in the stock.
In Q3 2025, the company reported no revenue and a net loss of $13.44 million, which increased by 144.76% YoY. EPS also remains negative at -0.25. The company has no gross margin, indicating a lack of operational profitability.
Analyst sentiment is overwhelmingly negative. On January 30, 2026, four analysts downgraded the stock, with one assigning a price target of $0. The downgrades are attributed to the failure of the company's Phase 3 trial and the discontinuation of its core program.
